The biotech market continues to show strong momentum. Heart drug developer Kardigan successfully made its trading debut on the Nasdaq on Thursday, with shares rising 1.6% right out of the gate.
The core financial metrics behind the blockbuster listing:
- The War Chest: Kardigan raised a massive $400 million to aggressively fund and scale its advanced cardiovascular pipeline.
- Upsized Demand: Strong institutional appetite forced the company to upsize the U.S. Initial Public Offering (IPO) from its original target.
This successful debut signals robust investor confidence in late-stage clinical developers and high-conviction therapeutic areas against a volatile macro backdrop.